Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Northwest Biotherapeutics (NWBO) over the last 16 years, with Sep 2025 value amounting to $4.6 million.

  • Northwest Biotherapeutics' Cash & Equivalents rose 55.15% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 55.15%. This contributed to the annual value of $2.2 million for FY2024, which is 2.30% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Cash & Equivalents stood at $4.6 million for Q3 2025, which was up 5.65% from $4.3 million recorded in Q2 2025.
  • Over the past 5 years, Northwest Biotherapeutics' Cash & Equivalents peaked at $15.2 million during Q4 2021, and registered a low of $1.4 million during Q2 2023.
  • Over the past 3 years, Northwest Biotherapeutics' median Cash & Equivalents value was $2.9 million (recorded in 2024), while the average stood at $3.5 million.
  • As far as peak fluctuations go, Northwest Biotherapeutics' Cash & Equivalents soared by 877.49% in 2021, and later slumped by 70.52% in 2023.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Cash & Equivalents stood at $15.2 million in 2021, then crashed by 54.08% to $7.0 million in 2022, then tumbled by 69.48% to $2.1 million in 2023, then increased by 2.30% to $2.2 million in 2024, then soared by 55.15% to $4.6 million in 2025.
  • Its last three reported values are $4.6 million in Q3 2025, $4.3 million for Q2 2025, and $2.8 million during Q1 2025.